JPWO2023160651A5 - - Google Patents

Info

Publication number
JPWO2023160651A5
JPWO2023160651A5 JP2024549466A JP2024549466A JPWO2023160651A5 JP WO2023160651 A5 JPWO2023160651 A5 JP WO2023160651A5 JP 2024549466 A JP2024549466 A JP 2024549466A JP 2024549466 A JP2024549466 A JP 2024549466A JP WO2023160651 A5 JPWO2023160651 A5 JP WO2023160651A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024549466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508779A (ja
JP2025508779A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/078127 external-priority patent/WO2023160651A1/zh
Publication of JP2025508779A publication Critical patent/JP2025508779A/ja
Publication of JP2025508779A5 publication Critical patent/JP2025508779A5/ja
Publication of JPWO2023160651A5 publication Critical patent/JPWO2023160651A5/ja
Pending legal-status Critical Current

Links

JP2024549466A 2022-02-24 2023-02-24 抗体及びその薬物コンジュゲート並びに用途 Pending JP2025508779A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202210172397 2022-02-24
CN202210172397.7 2022-02-24
CN202210916833.7 2022-08-01
CN202210916833 2022-08-01
CN202211183393 2022-09-27
CN202211183393.5 2022-09-27
PCT/CN2023/078127 WO2023160651A1 (zh) 2022-02-24 2023-02-24 一种抗体及其药物偶联物和用途

Publications (3)

Publication Number Publication Date
JP2025508779A JP2025508779A (ja) 2025-04-10
JP2025508779A5 JP2025508779A5 (https=) 2026-03-02
JPWO2023160651A5 true JPWO2023160651A5 (https=) 2026-03-02

Family

ID=87764835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024549466A Pending JP2025508779A (ja) 2022-02-24 2023-02-24 抗体及びその薬物コンジュゲート並びに用途

Country Status (8)

Country Link
US (1) US20250333541A1 (https=)
EP (1) EP4484446A1 (https=)
JP (1) JP2025508779A (https=)
KR (1) KR20240150773A (https=)
CN (1) CN118786146A (https=)
AU (1) AU2023225240A1 (https=)
CA (1) CA3244292A1 (https=)
WO (1) WO2023160651A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202543685A (zh) * 2024-03-04 2025-11-16 大陸商蘇州宜聯生物醫藥有限公司 抗體藥物偶聯物及其製備方法和用途
TW202600596A (zh) * 2024-03-04 2026-01-01 大陸商杭州中美華東製藥有限公司 抗FGFR2b抗體、其抗體藥物偶聯物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー/エス 組織因子に対するヒト抗体薬物結合体
MX2020005473A (es) * 2017-11-27 2020-08-27 Purdue Pharma Lp Anticuerpos humanizados que se dirigen al factor tisular humano.
CA3094313A1 (en) 2018-04-06 2019-10-10 Seattle Genetics, Inc. Camptothecin peptide conjugates
CN110575547B (zh) * 2018-06-07 2021-07-30 中国科学院上海药物研究所 靶向于tf的抗体-药物偶联物及其制法和用途
MX2021015974A (es) * 2019-07-03 2022-04-26 Iconic Therapeutics Inc Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados.
MX2023000499A (es) * 2020-07-10 2023-04-20 Iconic Therapeutics Inc Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular.
MX2023001163A (es) * 2020-07-27 2023-02-22 Tuojie Biotech Shanghai Co Ltd Conjugado de farmaco anticuerpo anti-cd79b, metodo de preparacion y uso farmaceutico del mismo.
MX2023008895A (es) 2021-02-09 2023-08-09 Medilink Therapeutics Suzhou Co Ltd Conjugado de sustancia bioactiva, metodo de preparacion y uso del mismo.

Similar Documents

Publication Publication Date Title
US11584801B2 (en) Anti-5T4 antibodies and antibody-drug conjugates
JP2025138756A (ja) 抗her2抗体-薬物コンジュゲート
EP3134125B1 (en) Antibody-drug-conjugate and its use for the treatment of cancer
ES2884844T3 (es) Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3
JPWO2023046202A5 (https=)
ES2728936T3 (es) Anticuerpos dirigidos contra CDH19 para melanoma
CA3118542A1 (en) Cdcp1-targeted therapies
IL314567A (en) Drug-conjugated antibody to HER3 and its use
CA3184403A1 (en) Anti-claudin 18.2 antibody and antibody-drug conjugate thereof
CN120548364A (zh) 抗lrrc15抗体
TW202417508A (zh) 抗trop2/egfr抗體及其用途
EP4470568A1 (en) Pharmaceutical composition comprising anti-cd79b antibody-drug conjugate and use thereof
TW202348252A (zh) 用治療性結合分子治療癌症的組合療法
JPWO2023160651A5 (https=)
KR20250084935A (ko) 링커-페이로드 화합물, 접합체 및 이의 응용 분야
CN120187456A (zh) 新降解剂缀合物
JP7594708B1 (ja) ネクチン4を標的としエキサテカンペイロードを含む抗体薬物コンジュゲート(adc)
RU2814164C2 (ru) Антитело против клаудина 18.2 и его конъюгат антитело-лекарственное средство
WO2025056748A1 (en) Antibody-drug conjugate
JP2025168320A (ja) タンパク質チロシンキナーゼ7抗体及び抗体-薬物コンジュゲート
CN120957758A (zh) 大环化合物及其制备方法和用途
RU2025119602A (ru) Антитело к c-met, конъюгат антитело-лекарственный препарат, способ их получения и их применение
EA051050B1 (ru) Конъюгат лекарственного средства производного эрибулина
NZ615308B2 (en) Antibody-drug conjugates